Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02229422
Other study ID # 140396
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2014
Est. completion date December 25, 2025

Study information

Verified date August 2023
Source University of California, San Diego
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We hypothesize that GA101 - Obinutuzumab in combination with HDMP is well tolerated and will induce similar if not higher response rates than the ones observed in Rituximab plus HDMP studies (Castro et al., 2009, Castro et al., 2008).


Description:

This is an open label phase Ib/II clinical trial to determine the safety and clinical activity of the GA101 - Obinutuzumab in combination with high-dose methylprednisone (HDMP). We will evaluate dose-limiting toxicities (DLTs) during the first month of therapy as part of the phase Ib of this study. In the phase II we will determine response rate in an intention to treat analysis. In this study we will include CLL patients that have never received treatment as well as patients that have failed previous treatments.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 40
Est. completion date December 25, 2025
Est. primary completion date October 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of CLL 2. Indication for treatment as defined by the IWCLL Guidelines (Hallek et al., 2008b). 3. Males and females 18 years of age and older. 4. Laboratory parameters as specified below: - Hematologic: Hemoglobin > 8 g/dL (may be post-transfusion); platelet count > 40 x103/mm3 (may be post-transfusion). Absolute neutrophil count > 1.0 109 cells/mm3 (Growth factor use is allowed). - Hepatic: Total Bilirubin < 3 x ULN, and ALT and AST < 3 x ULN - Renal: Creatinine clearance > 30 mL/min (Calculated according to institutional standards or using Cockcroft-Gault formula. Subjects with requirement of hemodialysis will be excluded). 5. ECOG Performance Status < 2, unless the decline of the performance status is considered to be related to CLL symptoms. 6. Anticipated survival of at least 6 months. 7. Subjects can be enrolled and treated under this protocol regardless of their CLL treatment history or number of previous treatments. In addition, subjects with history of allogeneic stem cell transplant can be enrolled and treated unless they have active manifestations of graft vs. host disease (GVHD) or chronic illness or infections that will prevent them from completing the study. 8. Previously untreated subjects that meet ANY of the following criteria: A. Documented refusal to be treated with chemotherapy agents. B. Subjects that are not candidates for treatment with chemotherapy based on poor performance status (ECOG = 2), advance age (> 65 years), Cumulative Illness Rating Scale (CIRS score) = 6 or cytopenias. 9. Effective contraception is required while receiving GA101 - Obinutuzumab. For women of childbearing potential and men, effective contraception is required while receiving GA101 - Obinutuzumab and for 365 days (12 months) after the last dose of the study drug. 10. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments. 11. Subjects must give written informed consent to participate in this trial. Exclusion Criteria: 1. Pregnant or nursing women. 2. Treatment with chemotherapy, monoclonal antibodies or biological agents (e.g. Ibrutinib, lenalidomide) within 28 days prior to entering the study. 3. Treatment with chemotherapy, monoclonal antibodies, biological agents (e.g. Ibrutinib) or other than the investigational agents during the time of participation in this trial. 4. Grade 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification. 5. Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, COPD) 6. Participation in any investigational drug study within 28 days prior to initiation of treatment within this protocol. 7. History of second malignancy, other than non-melanoma skin cancer or in situ carcinoma of the cervix or the breast, unless the tumor was successfully treated at least 2 years before trial entry and with no evidence of relapse or active cancer. 8. Active symptomatic fungal, bacterial and/or viral infection including evidence of infection with HIV, human T-cell leukemia virus 1 (HTLV-1) seropositive status. 9. Evidence of active acute or chronic Hepatitis B (HBV). 10. Evidence of active Hepatitis C (HCV): subjects with positive hepatitis C serology AND positive HCV RNA test. 11. Any illness or condition that in the opinion of the Investigator may affect safety of treatment or evaluation of any the study's endpoints. 12. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy 13. Known hypersensitivity to any of the study drugs. 14. Major surgery (within 4 weeks prior to the start of Cycle 1), except for procedures that are performed for diagnostic purposes. 15. Men or women of childbearing potential who refuse to use an adequate measure of contraception (oral contraceptives, intrauterine device, or barrier method of contraception in conjunction with spermicidal jelly) unless they have past medical history of surgical sterilization. 16. Vaccination with a live vaccine within 28 days of the initiation of treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GA101/HDMP
All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow: On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered. On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered. On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered. On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered. All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow: •On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered.

Locations

Country Name City State
United States UCSD Moores Cancer Center La Jolla California

Sponsors (2)

Lead Sponsor Collaborator
University of California, San Diego Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events that constitute the Dose Limiting Toxicity 2 months
Primary Response assessment based on IWCLL 2 months
Secondary Progression Free Survival 2 years
Secondary Overall Survival and Minimal residual disease (MRD) 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01862445 - Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Completed NCT00535873 - Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older Phase 2
Withdrawn NCT03639324 - Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Phase 1
Recruiting NCT05517265 - Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
Recruiting NCT03868722 - Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment Phase 2/Phase 3
Recruiting NCT04640909 - Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients N/A
Recruiting NCT05610228 - Study of the Metabolism in the Lymphatic Niche of CLL
Completed NCT01168921 - Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Phase 2
Withdrawn NCT05209308 - Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL Phase 2
Completed NCT00792077 - A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue Phase 2
Recruiting NCT06073821 - Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Phase 3
Recruiting NCT05246345 - Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01703364 - Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Phase 1/Phase 2
Terminated NCT03572634 - Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Phase 1/Phase 2
Completed NCT03231579 - Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
Completed NCT00636909 - Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Phase 2
Active, not recruiting NCT03524235 - Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Phase 1
Active, not recruiting NCT04746092 - The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19